Vir Biotechnology, Inc. (VIR) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Vir Biotechnology is a clinical-stage biopharmaceutical company focused on infectious diseases (specifically Chronic Hepatitis Delta) and oncology (dual-masked T-cell engagers). The company operates as a single reportable segment and continues to incur net losses while advancing its clinical pipeline.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $240 | $2,380 | $4,486 | $61,831 |
| Net Loss | $(163,141) | $(213,717) | $(395,064) | $(417,371) |
| Loss Per Share (Basic/Diluted) | $(1.17) | $(1.56) | $(2.86) | $(3.07) |
| Cash, Cash Equivalents & Investments | $810.7 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $1.15 billion (as of Sept 30, 2025) | |||
| Net Cash Used in Operating Activities (9M) | $(365.9 million) | $(358.7 million) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue for the nine months ended September 30, 2025, dropped significantly to $4.5 million from $61.8 million in the prior year. This was primarily driven by the expiration of GSK collaboration rights in Q1 2024 (which generated $51.7 million in deferred revenue recognition) and lower grant revenue from the Gates Foundation and BARDA.
- Expense Reductions: Operating expenses decreased by approximately $96 million for the nine-month period compared to 2024. This reduction is attributed to headcount reductions, the completion of restructuring initiatives, and the absence of the $102.8 million in-process research and development (IPR&D) expense recognized in Q3 2024 related to the Sanofi license agreement.
- Significant Milestone Payments: Despite overall cost savings, the company incurred specific large expenses in Q3 2025, including a $75.0 million milestone payment to Sanofi upon the first-in-human dosing of VIR-5525 and a $30.0 million payment to Alnylam Pharmaceuticals related to the Restated Alnylam Agreement.
- Liquidity Position: Cash and investments decreased from $1.09 billion at year-end 2024 to $810.7 million as of September 30, 2025, reflecting operating burn and milestone payments.
Guidance, Outlook, and Risks
- Clinical Progress: The ECLIPSE Phase 3 registrational program for Chronic Hepatitis Delta (CHD) is fully underway. ECLIPSE 1 enrollment completed ahead of schedule, with topline data expected in Q1 2027. Oncology programs (VIR-5500, VIR-5818, VIR-5525) are advancing in Phase 1.
- Liquidity Outlook: Management believes current cash, cash equivalents, and investments ($810.7 million) are sufficient to fund operations for at least the next 12 months from the filing date.
- Revenue Outlook: The company does not expect meaningful future revenue from sotrovimab (COVID-19) following the FDA revocation of its Emergency Use Authorization in December 2024. Future revenue is contingent on regulatory approval and commercialization of pipeline candidates.
- Risks: Key risks include the high uncertainty of clinical trial outcomes, the need for substantial additional capital to fund development, reliance on third-party CDMOs for manufacturing, and potential dilution from future equity financings.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $810.7 million cash balance against the projected burn rate, considering the high cost of Phase 3 trials and potential future milestone payments.
- Milestone Obligations: Review the remaining contingent consideration obligations ($34.2 million recorded) and future potential payments to Sanofi (up to $1.8 billion in milestones/royalties) and Alnylam.
- Grant Revenue Sustainability: Assess the impact of the Gates Foundation grant expiration and the return of $9.5 million in unused funds on future revenue streams.
- Sanofi Agreement Terms: Confirm the status of the $75 million escrowed milestone and the timeline for the remaining $323 million in development/regulatory milestones.
- Restructuring Completion: Validate that the cost savings from headcount reductions and site closures (St. Louis, Portland) are sustainable and not offset by new clinical trial costs.